Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2006

View Archived Issues

Preclinical and clinical results for ceftaroline reported at ICAAC

Hsp90 inhibition activates Fas apoptotic pathway in cultured motor neurons

Talabostat upregulates innate and acquired immunity against cancer cells

Phase I/II study of Cardeva begins dosing

Indian approval for glioblastoma trial of Cotara

Endo acquires RxKinetix

FDA requests additional data to support use of Fuzeon with needle-free device

Enrollment completed in skin cancer pilot study of PEP-005 Topical

TPM-02/insulin delivers insulin through skin in phase I trial

Gene Logic to seek alternative development paths for Lilly drug candidates

Ambrilia licenses HIV/AIDS protease inhibitor program rights to Merck & Co.

End-of-phase II meeting requested for Diamyd

SPA reached for phase II study of M-Vax in metastatic melanoma

EKR Therapeutics acquires North American rights for Gelclair

Dosing completed in twin phase III studies of PreHistin

Fresenius to acquire phosphate binder business from Nabi

Multispan and Medarex sign licensing agreement

Immune Response updates recent clinical progress

Recent patents disclose novel antiinfective agents

Recent Novartis and GSK patents impart new therapeutics for respiratory disorders

New agents for depression, psychosis, sleep disorders, etc., patented

AMG-517, a novel TRPV1 antagonist, from Amgen

SCH-697466: a novel gamma-secretase inhibitor profiled at the SfN meeting

Abbott and Icagen present a potent and selective Nav1.8 blocker with analgesic efficacy

Orphan drug designation for talactoferrin in renal cell carcinoma

Aricept approved for severe Alzheimer's disease

French approval for Loramyc for oropharyngeal candidiasis

Wyeth presents the neuroprotective effects of novel Src kinase inhibitor in stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...